Oncimmune Holdings PLC (LON:ONC) said it is “building momentum” with its ImmunoINSIGHTS offering after signing its fourth partnership agreement with a top-ten bio-pharma company in under four months.
Oncimmune’s expertise will be deployed to in a pilot programme to profile patients receiving a type of cancer drug called an immune checkpoint inhibitor.
Specifically, the aim is to assess which patients are most likely to tolerate and respond positively to the treatment.
The programme, which will see the deployment of the biomarker discovery engine, SeroTag, is expected to be concluded by in the second quarter of next year.
The aim for Oncimmune is to further validate the power of the ImmunoINSIGHTS service ahead of signing a “significantly larger partnership agreement in profiling patients on a range of immuno-oncology clinical trials”, investors were told.
“The momentum we are building with the world's largest companies in the pharmaceutical industry is a testament to the value that a collaboration with Oncimmune can bring to their development programmes,” the company's chief executive Adam Hill said in a statement.
“Through these recent agreements, we look forward to further demonstrating the potential of ImmunoINSIGHTS to have a tangible and complementary impact on immuno-oncology clinical trial outcomes," he added.